SUSD2

Summary

SUSD2 (sushi domain containing 2, HGNC:30667) is a protein-coding gene on chromosome 22q11.23, encoding Sushi domain-containing protein 2 (Q9UGT4). May be a cytokine receptor for GPR15LG.

Involved in negative regulation of cell cycle G1/S phase transition and negative regulation of cell division. Located in plasma membrane.

Source: NCBI Gene 56241 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 201 total
• Cancer driver (intOGen): activating (oncogene-like) across 1 cancer types
• MANE Select transcript: NM_019601

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30667
Approved symbol	SUSD2
Name	sushi domain containing 2
Location	22q11.23
Locus type	gene with protein product
Status	Approved
Aliases	BK65A6.2, FLJ22778, W5C5
Ensembl gene	ENSG00000099994
Ensembl biotype	protein_coding
OMIM	615825
Entrez	56241

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 8 protein_coding, 1 retained_intron

ENST00000358321, ENST00000463101, ENST00000886473, ENST00000886474, ENST00000886475, ENST00000886476, ENST00000886477, ENST00000959321, ENST00000959322

RefSeq mRNA: 1 — MANE Select: NM_019601 NM_019601

CCDS: CCDS13824

Canonical transcript exons

ENST00000358321 — 15 exons

Exon	Start	End
ENSE00000651656	24181487	24181595
ENSE00000651658	24183495	24183646
ENSE00000651659	24184136	24184303
ENSE00000651665	24186257	24186415
ENSE00000651666	24187202	24187450
ENSE00000651667	24187571	24187843
ENSE00001657986	24183057	24183267
ENSE00001889241	24188412	24189106
ENSE00003537597	24184766	24184940
ENSE00003584084	24185486	24185571
ENSE00003619757	24187959	24188135
ENSE00003634241	24188225	24188327
ENSE00003643487	24186016	24186159
ENSE00003658555	24185094	24185295
ENSE00003692948	24185661	24185929

Expression profiles

Bgee: expression breadth ubiquitous, 197 present calls, max score 99.28.

FANTOM5 (CAGE): breadth broad, TPM avg 10.6688 / max 1522.5114, expressed in 868 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
191366	10.6539	868
191365	0.0149	3

Top tissues by expression

247 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ileal mucosa	UBERON:0000331	99.28	gold quality
kidney epithelium	UBERON:0004819	98.24	gold quality
lower lobe of lung	UBERON:0008949	97.49	gold quality
right lung	UBERON:0002167	96.33	gold quality
upper lobe of lung	UBERON:0008948	95.53	gold quality
upper lobe of left lung	UBERON:0008952	95.40	gold quality
right coronary artery	UBERON:0001625	94.39	gold quality
popliteal artery	UBERON:0002250	93.65	gold quality
tibial artery	UBERON:0007610	93.61	gold quality
lung	UBERON:0002048	92.65	gold quality
left coronary artery	UBERON:0001626	92.22	gold quality
coronary artery	UBERON:0001621	91.69	gold quality
upper arm skin	UBERON:0004263	91.68	gold quality
dorsal root ganglion	UBERON:0000044	91.52	gold quality
adult organism	UBERON:0007023	91.25	gold quality
jejunal mucosa	UBERON:0000399	91.11	gold quality
visceral pleura	UBERON:0002401	89.85	gold quality
aorta	UBERON:0000947	89.30	gold quality
skin of leg	UBERON:0001511	87.38	gold quality
adult mammalian kidney	UBERON:0000082	86.92	gold quality
skin of abdomen	UBERON:0001416	86.74	gold quality
descending thoracic aorta	UBERON:0002345	86.32	gold quality
zone of skin	UBERON:0000014	86.11	gold quality
trigeminal ganglion	UBERON:0001675	85.88	gold quality
right lobe of thyroid gland	UBERON:0001119	85.50	gold quality
upper leg skin	UBERON:0004262	84.70	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	84.50	gold quality
endocervix	UBERON:0000458	83.92	gold quality
thoracic aorta	UBERON:0001515	83.83	gold quality
left lobe of thyroid gland	UBERON:0001120	83.71	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-3929	yes	679.45
E-MTAB-10018	yes	136.25
E-ANND-3	yes	23.25
E-GEOD-36552	no	133.79

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

45 targeting SUSD2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-7152-3P	99.97	67.47	849
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-6857-5P	99.87	65.32	985
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-3150A-3P	99.76	64.44	1640
HSA-MIR-6763-5P	99.76	64.68	1767
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-1200	99.71	70.42	1838
HSA-MIR-3934-5P	99.67	64.04	846
HSA-MIR-24-3P	99.59	69.97	1934
HSA-MIR-1915-3P	99.58	66.79	1988
HSA-MIR-4649-3P	99.56	66.90	1783
HSA-MIR-143-3P	99.49	69.05	1457
HSA-MIR-4770	99.49	69.09	1451
HSA-MIR-365A-3P	99.43	70.02	836
HSA-MIR-365B-3P	99.43	70.02	836
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-1294	98.91	69.26	1030
HSA-MIR-9986	98.91	69.28	1024
HSA-MIR-5000-3P	98.79	65.63	1251
HSA-MIR-4260	98.78	65.37	848
HSA-MIR-5197-3P	98.71	67.05	1905
HSA-MIR-6840-3P	98.68	65.95	1923
HSA-MIR-496	98.66	69.80	931
HSA-MIR-7155-5P	98.65	66.14	1290
HSA-MIR-4700-5P	98.63	67.43	1915
HSA-MIR-5572	98.55	65.84	970

Literature-anchored findings (GeneRIF, showing 16)

• Authors found significantly fewer CD4 tumor infiltrating lymphocytes in breast tumors expressing Susd2. (PMID:23131994)
• Two new susceptibility loci for amyotrophic lateral sclerosis in the Han Chinese population in chromosome 1, CAMK1G and chromosome 22, SUSD2 and CABIN1. (PMID:23624525)
• No evidence of association between polymorphisms in SUSD2 and sporadic amyotrophic lateral sclerosis in Han Chinese (PMID:25677198)
• Low SUSD2 expression is associated with renal cell carcinoma and lung cancer. (PMID:26815503)
• Tumors with high levels of SUSD2 staining contained 2-fold more tumor-associated macrophages, mainly of the M2 pro-angiogenic phenotype (PMID:28475599)
• suggest that SUSD2 counteracts senescence and cell death and is thus a potential chemotherapeutic target in human endometrial cancer (PMID:28841682)
• SUSD2 was identified as a candidate biomarker for hepatic recurrences of gastric cancer by transcriptome analysis. Patients with high SUSD2 expression were more likely to experience shorter disease-free and overall survival. Also, SUSD2 may reflect the malignant potential of gastric cancer and predict hepatic recurrences after curative resection. (PMID:30259711)
• platelet activation and binding to high-grade serous ovarian carcinoma cells was inversely correlated with the presence of SUSD2. This represents one of the first tumor proteins known to provide differential platelet interaction based on protein status. (PMID:30335544)
• TPM4 aggravates the malignant progression of hepatocellular carcinoma through negatively regulating SUSD2. (PMID:32432739)
• Genetic variants in SUSD2 are associated with the risk of ischemic heart disease. (PMID:32620384)
• Cultured cardiac fibroblasts and myofibroblasts express Sushi Containing Domain 2 and assemble a unique fibronectin rich matrix. (PMID:33453237)
• CircTOP2A acts as a ceRNA for miR346 and contributes to glioma progression via the modulation of sushi domaincontaining 2. (PMID:33537815)
• LncRNA small nucleolar RNA host gene 16 (SNHG16) silencing protects lipopolysaccharide (LPS)-induced cell injury in human lung fibroblasts WI-38 through acting as miR-141-3p sponge. (PMID:33836533)
• miR-141-3p promotes retinoblastoma progression via inhibiting sushi domain-containing protein 2. (PMID:35259051)
• CBX8 Together with SET Facilitates Ovarian Carcinoma Growth and Metastasis by Suppressing the Transcription of SUSD2. (PMID:35894945)
• The dual role of SUSD2 in cancer development. (PMID:38897441)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	SUSD2	ENSDARG00000101452
mus_musculus	Susd2	ENSMUSG00000006342
rattus_norvegicus	Susd2	ENSRNOG00000033389
drosophila_melanogaster	mesh	FBGN0051004
caenorhabditis_elegans		WBGENE00010047
caenorhabditis_elegans		WBGENE00010540
caenorhabditis_elegans		WBGENE00011175

Paralogs (2): MUC4 (ENSG00000145113), RTL9 (ENSG00000243978)

Protein

Protein identifiers

Sushi domain-containing protein 2 — Q9UGT4 (reviewed: Q9UGT4)

All UniProt accessions (2): Q9UGT4, A0A140VJW3

UniProt curated annotations — full annotation on UniProt →

Function. May be a cytokine receptor for GPR15LG. May be a tumor suppressor; together with GPR15LG has a growth inhibitory effect on colon cancer cells which includes G1 cell cycle arrest. May play a role in breast tumorigenesis.

Subunit / interactions. Interacts with LGALS1; leads to an increased amount of LGALS1 on the cell surface. Interacts with GPR15LG; the interaction is direct.

Subcellular location. Cell membrane.

Tissue specificity. Highly expressed in breast cancer, but shows a restricted expression pattern in normal tissues such as adipose, adrenal gland, kidney, lung, mammary gland, placenta, thyroid, trachea, and uterus. Also expressed in colon; down-regulated in colon cancer tissues.

RefSeq proteins (1): NP_062547* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000436	Sushi_SCR_CCP_dom	Domain
IPR001212	Somatomedin_B_dom	Domain
IPR001846	VWF_type-D	Domain
IPR005533	AMOP_dom	Domain
IPR035976	Sushi/SCR/CCP_sf	Homologous_superfamily
IPR036024	Somatomedin_B-like_dom_sf	Homologous_superfamily
IPR051495	Epithelial_Barrier/Signaling	Family
IPR056619	C8-3_MUC4	Domain

Pfam: PF00084, PF00094, PF03782, PF23263

UniProt features (25 total): disulfide bond 9, domain 4, glycosylation site 3, sequence variant 3, topological domain 2, signal peptide 1, chain 1, sequence conflict 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UGT4-F1	91.22	0.82

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (9): 31–44, 31–35, 35–62, 42–55, 42–44, 48–54, 55–62, 725–765, 751–778

Glycosylation sites (3): 177, 522, 162

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 98 (showing top): GOBP_NEGATIVE_REGULATION_OF_CELL_DIVISION, PEREZ_TP63_TARGETS, GOBP_CELL_CYCLE_PHASE_TRANSITION, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE, GOBP_REGULATION_OF_CELL_CYCLE, GOBP_REGULATION_OF_CELL_CYCLE_G1_S_PHASE_TRANSITION, GOBP_CELL_CYCLE_G1_S_PHASE_TRANSITION, GOBP_REGULATION_OF_CELL_DIVISION, PEREZ_TP53_AND_TP63_TARGETS, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_G1_S_PHASE_TRANSITION, GOBP_REGULATION_OF_CELL_CYCLE_PHASE_TRANSITION, YAMAZAKI_TCEB3_TARGETS_UP, GOBP_REGULATION_OF_CELL_CYCLE_PROCESS, GOBP_CELL_DIVISION

GO Biological Process (2): negative regulation of cell division (GO:0051782), negative regulation of cell cycle G1/S phase transition (GO:1902807)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (4): obsolete extracellular space (GO:0005615), plasma membrane (GO:0005886), extracellular exosome (GO:0070062), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
negative regulation of cellular process	1
cell division	1
regulation of cell division	1
cell cycle G1/S phase transition	1
negative regulation of cell cycle phase transition	1
regulation of cell cycle G1/S phase transition	1
binding	1
membrane	1
cell periphery	1
extracellular vesicle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

734 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SUSD2	GPR15LG	Q6UWK7	742
SUSD2	SUSD1	Q6UWL2	511
SUSD2	MCAM	P43121	507
SUSD2	ISM1	B1AKI9	498
SUSD2	PDGFRB	P09619	480
SUSD2	KLF17	Q5JT82	480
SUSD2	ISM2	Q6H9L7	415
SUSD2	NT5E	P21589	397
SUSD2	TSR1	Q2NL82	396
SUSD2	CSMD2	Q7Z408	394
SUSD2	ENG	P17813	391
SUSD2	HPCAL1	P37235	391
SUSD2	FAU	P35544	383
SUSD2	SCN9A	Q15858	383
SUSD2	ERAP2	Q6P179	383

IntAct

23 interactions, top by confidence:

A	B	Type	Score
TNS2	SUSD2	psi-mi:“MI:0915”(physical association)	0.560
KRTAP10-8	SUSD2	psi-mi:“MI:0915”(physical association)	0.560
LGALS1	LAMA5	psi-mi:“MI:0914”(association)	0.530
SUSD2	Dlg4	psi-mi:“MI:0407”(direct interaction)	0.440
TMEM106A	TMEM131L	psi-mi:“MI:0914”(association)	0.350
HLA-G	TMEM131L	psi-mi:“MI:0914”(association)	0.350
NAAA	HAX1	psi-mi:“MI:0914”(association)	0.350
SDF2L1	MANBA	psi-mi:“MI:0914”(association)	0.350
ECEL1	ADAM10	psi-mi:“MI:0914”(association)	0.350
CLEC2B	ADAM10	psi-mi:“MI:0914”(association)	0.350
UGT1A7	ADAM10	psi-mi:“MI:0914”(association)	0.350
ADAM30	ADAM10	psi-mi:“MI:0914”(association)	0.350
ST8SIA3	B3GAT3	psi-mi:“MI:0914”(association)	0.350
PLPPR2	BCL2L1	psi-mi:“MI:0914”(association)	0.350
SUSD2	UGGT1	psi-mi:“MI:0915”(physical association)	0.000
SUSD2	LGALS1	psi-mi:“MI:0915”(physical association)	0.000
SUSD2	TNS2	psi-mi:“MI:0915”(physical association)	0.000
SUSD2	KRTAP10-8	psi-mi:“MI:0915”(physical association)	0.000
SUSD2		psi-mi:“MI:0915”(physical association)	0.000
bclA	SUSD2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (19): LGALS1 (Affinity Capture-MS), UGGT1 (Affinity Capture-MS), TENC1 (Two-hybrid), KRTAP10-8 (Two-hybrid), SUSD2 (Affinity Capture-MS), SUSD2 (Affinity Capture-MS), SUSD2 (Affinity Capture-MS), SUSD2 (Affinity Capture-MS), SUSD2 (Affinity Capture-MS), SUSD2 (Affinity Capture-MS), SUSD2 (Affinity Capture-MS), SUSD2 (Affinity Capture-MS), SUSD2 (Affinity Capture-MS), SUSD2 (Affinity Capture-MS), SUSD2 (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GTW7, A0A1D5NSK0, A0A1L8HYT7, A0A286YEC0, G7PWZ3, O77755, O88959, P0C0K7, P17490, P23276, P43021, P51882, P59509, P59996, P70505, Q02853, Q04912, Q04962, Q04997, Q0V8J4, Q0VAY3, Q17R55, Q3U435, Q499S5, Q4R7Z5, Q58Y75, Q62190, Q6MG64, Q76MJ5, Q7TN88, Q7Z442, Q80W65, Q8BMN4, Q8CJH3, Q8IVN8, Q8VCS0, Q91X21, Q96KR4, Q96PQ0, Q96S42

Diamond homologs: A0A1D5NSM8, A2AVA0, C1IBY0, O35086, P00738, P00739, P00751, P04186, P06681, P08174, P0C6B8, P11034, P13366, P19007, P20851, P21180, P28175, P28293, P35588, P49457, P50417, P81187, P81475, P85202, Q03710, Q22328, Q26422, Q27081, Q28506, Q28801, Q3SYW2, Q53EL9, Q5R5F6, Q5VAN1, Q60574, Q6IE14, Q6P1D5, Q7TSK2, Q7Z407, Q7Z408

SIGNOR signaling

0 interactions.

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 1 cancer types — LUSC.

Clinical variants and AI predictions

ClinVar

201 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	166
Likely benign	17
Benign	5

Top pathogenic / likely-pathogenic (0)

SpliceAI

2272 predictions. Top by Δscore:

Variant	Effect	Δscore
22:24184129:T:TA	acceptor_gain	1.0000
22:24184132:CCAGT:C	acceptor_loss	1.0000
22:24184133:CA:C	acceptor_loss	1.0000
22:24184134:A:AG	acceptor_gain	1.0000
22:24184134:AGT:A	acceptor_gain	1.0000
22:24184135:G:GA	acceptor_gain	1.0000
22:24184135:GT:G	acceptor_gain	1.0000
22:24184135:GTG:G	acceptor_gain	1.0000
22:24184135:GTGC:G	acceptor_gain	1.0000
22:24184135:GTGCA:G	acceptor_gain	1.0000
22:24184299:GACAG:G	donor_gain	1.0000
22:24184301:CAGG:C	donor_loss	1.0000
22:24184303:GGT:G	donor_loss	1.0000
22:24184304:G:GG	donor_gain	1.0000
22:24184938:GAA:G	donor_gain	1.0000
22:24184941:G:GG	donor_gain	1.0000
22:24185089:CACA:C	acceptor_loss	1.0000
22:24185092:A:AG	acceptor_gain	1.0000
22:24185092:A:T	acceptor_loss	1.0000
22:24185092:AG:A	acceptor_gain	1.0000
22:24185092:AGG:A	acceptor_gain	1.0000
22:24185093:G:GG	acceptor_gain	1.0000
22:24185093:GG:G	acceptor_gain	1.0000
22:24185093:GGG:G	acceptor_gain	1.0000
22:24185093:GGGAC:G	acceptor_gain	1.0000
22:24185233:G:GT	donor_gain	1.0000
22:24185236:G:GT	donor_gain	1.0000
22:24185293:TTC:T	donor_gain	1.0000
22:24185294:TC:T	donor_gain	1.0000
22:24185296:G:GG	donor_gain	1.0000

AlphaMissense

5342 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
22:24185134:T:A	W275R	0.997
22:24185134:T:C	W275R	0.997
22:24184192:T:A	W166R	0.994
22:24184192:T:C	W166R	0.994
22:24184907:G:C	R250P	0.994
22:24185110:T:A	W267R	0.994
22:24185110:T:C	W267R	0.994
22:24184194:G:C	W166C	0.993
22:24184194:G:T	W166C	0.993
22:24185136:G:C	W275C	0.993
22:24185136:G:T	W275C	0.993
22:24185112:G:C	W267C	0.992
22:24185112:G:T	W267C	0.992
22:24185856:G:C	W422C	0.992
22:24185856:G:T	W422C	0.992
22:24188107:G:C	W771C	0.991
22:24188107:G:T	W771C	0.991
22:24185199:G:C	W296C	0.988
22:24185199:G:T	W296C	0.988
22:24185522:T:A	C341S	0.987
22:24185523:G:C	C341S	0.987
22:24185825:A:T	D412V	0.987
22:24185188:T:A	C293S	0.986
22:24185189:G:C	C293S	0.986
22:24185551:T:G	C350W	0.985
22:24188126:T:A	C778S	0.985
22:24188127:G:C	C778S	0.985
22:24183637:T:A	W144R	0.984
22:24183637:T:C	W144R	0.984
22:24184285:T:A	W197R	0.984

dbSNP variants (sampled 300 via entrez): RS1000280624 (22:24179602 G>A,T), RS1000289225 (22:24188243 T>C), RS1001097649 (22:24182783 A>G), RS1001158049 (22:24182550 A>C), RS1002216923 (22:24187186 T>A), RS1002354554 (22:24180564 G>A), RS1002616089 (22:24182266 G>A,T), RS1003249502 (22:24188757 C>T), RS1003594808 (22:24181406 C>A,G,T), RS1003621575 (22:24181355 C>G,T), RS1003803304 (22:24185752 C>A,T), RS1004156502 (22:24187161 G>A,T), RS1004295953 (22:24186958 G>A), RS1005109924 (22:24180808 A>G), RS1005162064 (22:24188373 G>A,C)

Disease associations

OMIM: gene MIM:615825 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST001981_2	Amyotrophic lateral sclerosis	2.000000e-09
GCST002481_6	Acne (severe)	6.000000e-07
GCST005196_252	Coronary artery disease	1.000000e-07

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

51 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	decreases expression, affects expression, increases abundance, increases expression	4
Tobacco Smoke Pollution	affects expression, decreases expression	3
Particulate Matter	decreases expression, increases abundance, increases expression	3
sodium arsenite	decreases expression, increases expression	2
butylbenzyl phthalate	decreases expression, affects cotreatment	2
entinostat	increases expression, affects cotreatment	2
Panobinostat	affects cotreatment, increases expression	2
Benzo(a)pyrene	affects methylation, increases expression, increases methylation	2
Diethylhexyl Phthalate	affects cotreatment, decreases expression, increases expression	2
Nickel	decreases expression	2
Valproic Acid	affects expression, increases methylation	2
Cadmium Chloride	decreases expression, increases abundance, increases expression	2
aristolochic acid I	increases expression	1
perfluorotetradecanoic acid	increases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
lead acetate	decreases expression	1
diisononyl phthalate	affects cotreatment, decreases expression	1
arsenite	increases expression	1
lead nitrate	affects cotreatment, decreases expression	1
perfluorooctanoic acid	affects expression	1
cupric chloride	decreases expression	1
perfluorobutyric acid	decreases expression	1
perfluoro-n-nonanoic acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	increases expression, affects cotreatment	1
incobotulinumtoxinA	decreases expression	1
(+)-JQ1 compound	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.